Early Look

Friday, November 20, 2026

Futures

Up/Down

%

Last

Dow

-11.00

0.02%

49,169

S&P 500

-51.25

0.71%

7,146

Nasdaq

-427.50

1.61%

26,172

 

 

The pain continues on Wall Street, with U.S. futures extending Thursday’s broad based sell off, this time taking global markets lower as well as the AI trade remains rattled by growth and valuation concerns, while hawkish signals from Federal Reserve officials this week also weighed on sentiment. Stocks closed sharply lower on Thursday and the tech sell-off continues to astound over the last 3 months, while the S&P 500 index fell for a 6th straight day in what has been a stunning turn of events in the Ai sector from Wall Street darlings to being the least favored sector. In Asian markets, The Nikkei Index plunged -3,000 points or 5.06% to 56,436, the Shanghai Index fell -43 points to 3,533,  the Korean Kospi tumbled -44 points or 5.53% to 755, and the Hang Seng Index declined -430 points to 22,410. In Europe, the German DAX is falling -444 points or 1.75% to 25,019, while the FTSE 100 is down -54 points to 10,397. Anthropic (ANT) shares slid more than -6% in premarket trading after surging more than 17% on Thursday in their highly anticipated market debut. The stock began trading more than 34% above its offer price of $83, but is tumbling along with the rest of tech as Nasdaq futures are down over -1.5% after falling 2.25% on Thursday. The Nasdaq comes into this option expiration Friday roughly 13.6% below its record closing high of October 6. US Treasury yields dropped on Friday as jitters about the AI trade weighed on global equities and led investors to seek out safe-haven assets. The 2-year yield was last down around 6 bps to 4.7194% and down over 15 basis points this week so far, on track for its steepest weekly drop since mid-2025. Bitcoin slumped to a near five-month low on Friday and was headed for a seventh straight week of losses. Oil prices are set for a third straight weekly decline on strong Middle East export flows (Brent set for weekly decline of 5%, WTI on track for 7% drop). The U.S. Dollar (DXY) near 19-month high, set for 4th weekly gain as AI worries fuel haven bid. U.S. stock markets are on track for sizable weekly losses, with major averages falling well below their 200dma supporting technical averages in a broad based selloff with all 11 S&P sectors down on the week. Gold prices extend their plunge as well.

 

Market Closing Prices Yesterday

  • The S&P 500 Index dropped -147.80 points, or 2.02%, to 7,175.83
  • The Dow Jones Industrial Average fell -1,101.11 points, or 2.19%, to 49,097.06
  • The Nasdaq Composite tumbled -550.69 points, or 2.25%, to 23,879.20
  • The Russell 2000 Index declined -59.17 points, or 2.18% to 2,655.50

Economic Calendar for Today

  • 10:00 AM ET                 University of Michigan Confidence, Nov-Final
  • 10:00 AM ET                 University of Michigan 1-yr and 5-yr inflation expectation, Nov -Final
  • 1:00 PM ET                    Baker Hughes Weekly rig count data

Earnings Calendar:

  • Earnings Before the Open: BJ BKE BSP FRO RLX WRD

Other Key Events:

  • Deutsche Bank Gaming, Lodging, Leisure One on One Conference 11/19-11/20, in Miami, FL
  • Supercomputing 2026, 11/15-11/20, in New Orleans

 

 

Macro

Up/Down

Last

Nymex

-0.81

82.40

Brent

-0.56

91.42

Gold

-96.10

3,589.40

EUR/USD

-0.0003

1.0964

JPY/USD

-0.87

158.82

10-Year Note

-0.062

4.98%

 

World News

  • Japan’s national core CPI rose +2.2% YoY in October (est. +2.3%, prev. +2.1%), its fastest pace since December 2025. Headline was +2.3% YoY (est. +2.5%, prev. +2.1%), and CPI ex fresh food and energy slowed to +2.2% YoY (est. +2.3%, prev. +2.4%). Energy accounted for the core acceleration, turning to +2.2% YoY.
  • Fed’s Goolsbee said all policy options remain on the table ahead of next month's Fed meeting, including a larger rate hike, after several months of stubbornly high inflation.
  • Fed’s Paulson said the Fed still has further tightening ahead as inflation remains too high. She said restoring price stability is the top priority and that a deliberate pace of rate hikes allows policymakers to gauge the economy's response to tighter policy.

Sector News Breakdown

Consumer

  • Gap Inc. (GAP) Q3 Adjusted EPS $0.82 vs. est. $0.78 (beat), sales $4.00B vs. est. $4.02B (miss), comparable sales flat and adjusted operating Income $393Mm; sees Q4 sales flat to down 1% Y/Y vs est +3.19% (below) and gross margin 38.0%-38.3%; cuts FY26 adjusted EPS to $2.29-$2.34 from $2.35-$2.45 vs. est. $2.39 (below), sees sales roughly flat vs. prior growth of 1%-1.5% and adjusted operating margin 7.2%.
  • Natural Grocers (NGVC) Q4 EPS $0.48 vs. est. $0.55 (miss), sales $347.5Mm vs. est. $352.6Mm (miss), adjusted EBITDA $24.9Mm vs est $26.71Mm (miss), gross profit $101.7Mm and gross margin 29.2%.
  • Post Holdings (POST) Q4 adj EPS $1.84 vs. consensus $1.78; q4 sales $2.0B in-line with estimates; Q4 operating income $205.1M and adj Ebitda $378.4M; Post Holdings Executive Chairman Robert V. Vitale taking medical leave; director Jeff A. Zadoks named interim chairman during his absence.
  • Ross Stores (ROST) Q3 EPS $1.91 vs. est. $1.88 (beat), sales $6.256B vs. est. $6.255B (in line), comparable-store sales up 8%, operating Income $766.8Mm and operating margin 12.3%; sees Q4 EPS $2.16-$2.25 vs est $2.28 (below) and comparable-store sales growth of 4%-5%; sees FY26 EPS $8.75-$8.84 vs. est. $8.70 (above).
  • U.S. lawmakers are nearing an agreement on legislation to ban Chinese cars from the domestic market, with last-minute negotiations focused partly on protecting Mercedes-Benz, which is nearly 20% owned by Chinese entities, Bloomberg reported. The measure would further restrict Chinese automakers such as BYD (BYDDF) and Geely (GELYF) from accessing the US market.

Energy, Industrials and Materials

  • ESCO Technologies (ESE) Q4 adj EPS $2.67 vs. est. 42.60; Q4 sales $384M vs. est. $375.6M; FY27 net sales are expected to grow 55% to 58% to a range of $2.05B-$2.09B on a consolidated basis; Q4 2026 entered orders increased $71M (22%) to $392M (book-to-bill of 1.02x).
  • Marathon Petroleum (MPC) declared force majeure on North Dakota oil pipeline deliveries after a flurry of crude contamination issues, Bloomberg reported late Wednesday.
  • Matthews International (MATW) Q4 adj EPS $0.39 vs. est. $0.27; Q4 sales fell -20% y/y to $256.7M vs. est. $252.7M; Q4 operating margin negative -3.3%; Q4 net loss narrowed 29% y/y to $19.5M; withheld full-year FY27 guidance, citing economic uncertainty, litigation affecting its engineering business and ongoing strategy development.
  • Oklo (OKLO) upgraded to Buy at Guggenheim with $38 PT, coming away with the Q3 business update encouraged by Oklo's execution on key milestones, while also noting that the stock has fallen by 80% from its January peak.
  • SpaceX (SPCX) sold $32B of bonds to fund its purchase of artificial intelligence chips on Thursday, in a complicated and relatively high-yielding transaction that may serve as a model for a wave of similar financings to come, according to a Bloomberg report. The debt offering was designed to keep the borrowing off SpaceX’s balance sheet and is part of a more than $40B financing that also includes bank loans.

Financials

  • Intuit Corp. (INTU) Q1 Adjusted EPS $2.91 vs. est. $2.70 (beat); revenue $4.354B vs. est. $4.305B (beat); sees Q2 adjusted EPS $3.17-$3.22 vs. est. $3.98 (below) and revenue $4.93B-$4.95B vs. est. $5.11B (below); sees FY27 adjusted EPS $22.88-$23.12 vs. est. $23.62 (below) and revenue $23.08B-$23.37B vs. est. $23.43B (below), excluding any impact from the pending $3.68B Mailchimp sale to Bending Spoons.
  • LPL Financial (LPLA) monthly activity report for October. Total client assets at the end of October were $2.56T, a decrease of $3.7B, or 0.1%, compared to the end of September. Advisory assets as a percentage of total assets was 60.9%, up from 58.5% a year ago. Total organic net new assets for October were $7B, translating to a 3.3% annualized growth rate. Total client cash balances at the end of October were $55.9B.
  • Webull Corp. (BULL) Q3 EPS $0.06 vs est $0.06 (in line), revenue $218.7Mm vs. est. $218.4Mm (in line), up 39% Y/Y, and adjusted operating Income $70Mm.

Healthcare

  • Bausch + Lomb (BLCO) reports phase 2 findings for bl1332 in post-surgical Ocular pain; said BL1332 doses show greater pain relief than vehicle; primary endpoint not met; study does not meet primary endpoint of pain Intensity improvement over 24 hours.
  • Celldex Therapeutics (CLDX) phase 2 barzolvolimab study in atopic dermatitis did not meet key efficacy measures; discontinues development of barzolvolimab in atopic dermatitis.

Technology, Media & Telecom

  • The Trump administration approved nearly 900,000 advanced artificial intelligence chips made by Nvidia (NVDA) and Advanced Micro Devices (AMD) for Chinese companies between December 2025 and May 2026, according to the House Foreign Affairs Committee on Thursday. The approvals included 75,000 chips for Alibaba (BABA), 150,000 for Tencent (TCEHY), 43,000 for Baidu (BIDU), and 4,000 for BYD (BYDDY) per the report.
  • Alphabet (GOOGL) plans to raise C$6 billion ($4.19 billion) through a multi-tranche offering of unsecured notes in the Canadian market, according to pricing terms released by the company.
  • Bending Spoons (BSP) Q3 Adj EPS $0.42 vs. est. $0.30 (beat), revenue $780.222Mm vs. est. $745.7Mm (beat), up 125% Y/Y with 3% organic growth, and adj operating Income $423.839Mm, up 130%, at a 54% margin; sees Q4 revenue $984Mm-$1.00B vs est $856.13M (above) and adjusted operating Income $470Mm-$490Mm; raises FY26 revenue guidance to $3.07B-$3.09B vs. est. $2.90B (above) from $2.78B-$2.82B and adjusted operating Income to $1.58B-$1.60B from $1.46B-$1.51B; announces $3.68B Mailchimp deal and $1.3B private share placement;
  • Elastic (ESTC) Q2 Adj EPS $0.94 vs. est. $0.81 (beat), revenue $495.947Mm vs. est. $486.6Mm (beat), up 17% Y/Y, and adjusted operating Income $110Mm vs. est. $92Mm (beat), with margin 22.2%; cRPO $1.157B, up 19% Y/Y, net expansion rate approximately 111%, adjusted FCF $44Mm and new $500Mm buyback authorization including $45Mm remaining under the prior program; sees Q3 adjusted EPS $0.90-$0.92 vs. est. $0.95 (below), revenue $507.5Mm-$508.5Mm vs. est. $517.5Mm (below) and adjusted operating margin 21%; sees FY27 adjusted EPS $3.35-$3.41 vs. est. $3.36 (in line), revenue $2.000B-$2.008B vs. est. $2.01B (below).
  • Globant SA (GLOB) Q3 Adjusted EPS $1.48 vs. est. $1.48 (in line), revenue $611.1Mm vs. est. $611.1Mm (in line), and adjusted gross margin 36.8%; sees Q4 adjusted EPS $1.43-$1.53 vs. est. $1.53 (below at midpoint) and revenue $596Mm-$604Mm vs. est. $610.2Mm (below); sees FY26 adjusted EPS $5.77-$5.87 vs. est. $5.91 (below) and revenue $2.429B-$2.437B vs. est. $2.45B.
  • Keysight Technologies (KEYS) Q4 adj EPS $3.61 vs. consensus $3.38 and revs $1.99B vs. est. $1.95B; sees Q1 adj EPS $3.63-$3.69, above consensus $3.25 and revs $2.04B-$2.06B vs. est. $1.98B.
  • SK Hynix (SKHY) will become the largest shareholder in Japanese chipmaker Kioxia Holdings (KXIAY) after converting bonds held through an investment vehicle into shares in December. SKHY said it would convert the bonds into 129,000 common shares and purchase an additional 1,001 shares in the investment vehicle from Bain Capital. The transaction will give SK Hynix an indirect stake of about 14.1% in Kioxia.

Mid-Morning Look

Friday, November 20, 2026

Index

Up/Down

%

Last

DJ Industrials

125.23

0.25%

49,222

S&P 500

-65.35

0.91%

7,110

Nasdaq

-478.75

2.00%

23,400

Russell 2000

-3.09

0.12%

2,652

 

 

U.S. stock markets tumbled again on Friday, in what has been a tumultuous week where all eleven S&P sectors are on track to finish notably lower (tech the worst) as the landscape for stock markets has become more of a minefield, with lots for investors to worry about. Among the reasons for tumbling stock markets include the “hawkish” Fed (several Fed speakers this week ramping up rate hike fears), a potentially less friendly Congressional legislative environment for tech companies (after the Blue Wave sweep of Congress by Democrats in midterm election), and rising concerns about global growth weigh heavily on risky assets. Consumer Staples (XLP +2%), Healthcare (XLV +1.1%) and REITs (XLRE +1.15%) leading markets early as defensive sectors rebound, but heavily weighted Technology (XLK) -3.9% remaining the biggest drag (down -8% this week alone). Gold's bearish spell continued as it falls to a 14-month low and headed for its worst week in eight months, amid pressure from a hawkish rates outlook and an AI-linked stocks selloff. has shed about -9% so far this week, the most since the week ended March 20, while silver came into the day down roughly 13% this week and is now down 66% or so off the January peak.

 

The heart of the tech sell off remains the AI sector, as shares of Anthropic (ANT), which priced its 980M share IPO at $83 on Thursday, opened at $111.50, and traded to highs around $115 has now traded below the $86 level this morning as Wall Street continues to exhibit concern over the AI trade. The debut did little to revive excitement around the broader AI trade as investors continued to question whether the massive spending would deliver returns. The semi index (SOX) fell over 4% this morning, hitting fresh 2-week lows, dented greatly on AI fears and the recent ousting of NVDA CEO Jensen. Asian stocks had the worst week since the coronavirus pandemic as Taiwan’s tech-heavy Taiex Index plunged 6.2% today, extending its weekly decline to almost 18%, biggest weekly loss since 1991. The CBOE Volatility index (VIX) jumped as high as 31.59 before dipping back under the 30 level (fell short of YTD high 35.30 on March 9, 2026). Treasury yields fell as bonds rallied, but precious metals, Bitcoin remain pressured (back to $60K) on track for 7th straight weekly drop on rate hike fears and rotation into the dollar trading at 19 month highs.

Economic Data

  • University of Michigan surveys of consumers sentiment final Nov 51.5 (consensus 51.5) vs preliminary Nov 51.0 and final Oct 48.0 as the current conditions index final Nov 49.4 (consensus 51.6) vs prelim Nov 51.0 and final Oct 46.7 and the expectations index final Nov 52.9 vs prelim Nov 50.9 and final Oct 48.8.
  • University of Michigan surveys of consumers 1-year inflation outlook final Nov 3.7% vs prelim 4.3% and final Oct 4.7% and surveys of consumers 5-year inflation outlook final Nov 3.3% vs prelim 3.4% and final Oct 3.5%.

 

 

Macro

Up/Down

Last

WTI Crude

-0.85

82.36

Brent

-1.46

90.52

Gold

-144.00

3,541.50

EUR/USD

0.0019

1.0986

JPY/USD

-0.88

158.71

10-Year Note

-0.084

4.968%

 

Stock GAINERS

  • BSP +3%; after better results with Q3 adj EPS $0.42 above est. $0.30 and revs $780.22Mm vs. est. $745.7Mm, up 125% Y/Y with 3% organic growth, and adj operating Income $423.839Mm, up 130%; also raises FY26 revenue guidance to $3.07B-$3.09B vs. est. $2.90B (above) from $2.78B-$2.82B.
  • EVH +15%; was upgraded to Buy from Hold with an unchanged $6 PT at Truist Securities, which sees policy fears overshooting fundamentals as improved visibility into 2027 EBITDA and a more attractive valuation skew the risk/reward favorably.
  • GAP +17%; Total sales grew 2%, with comps flat vs. est. +1.3%, and EPS of $0.82 (above views) as SG&A leverage offset flat GM. GAP reduced F26 sales guidance to roughly flat from +1-1.5% and EPS to $2.29-2.34 from $2.35-2.45 following softer demand in Oct from warmer weather. Gap comp was +9%
  • HUM +4%; along with a rebound in UNH shares in managed care after being upgraded from Hold to Buy (tgt to $485 from $430) at TD Cowen saying FY26 performance, 2027 Medicare Advantage benefits, and 2028 Stars results support a meaningful 2027 EPS step-up and more than $40 EPS in 2028
  • MKC +4%; as investors rotate into defensive food related stocks GIS, CPB, CAG, PEP, SJM, others
  • RVMD +2%; said its FDA-approved treatment Rasonque, used with standard chemotherapy, shrank tumors and curbed disease progression in an early-to-mid-stage study of patients with metastatic pancreatic cancer; study enrolled 61 patients who received Rasonque, together with gemcitabine and nab-paclitaxel.

 

Stock LAGGARDS

  • ABVX -11%; shares tumbled after Scorpion Capital publishes an 11-month investigation alleging that obefazimod's mechanism of action and safety claims are unreliable; the short seller claims its independent laboratory studies identified potential toxicity and contradictions in the drug's reported mechanism.
  • ANT -11%; which priced its 980M share IPO at $83 Thursday, opened at $111.50, and traded to highs around $115 has now traded below the $86 level as Wall Street continues to exhibit concern over the AI trade.
  • AVGO -4%; after analyst @mingchikuo said on X, “my latest industry survey indicates Google has cut 2027 shipments of the Broadcom-designed TPU 8i series by ~1M units (mostly the higher-priced 8i Max / Whalefish). The cut amounts to roughly 20% of 2027 TPU 8i series shipments."
  • BLTE -13%; after saying the FDA has extended the review period for its drug tinlarebant being developed for the treatment of Stargardt disease type 1 by three months; new action date is May 12, 2027; says if no major deficiencies are identified during the FDA's review, the agency expects to provide proposed labeling and any potential postmarketing requirements by April 12.
  • INTU -5%; after Q1 revenue and adjusted EPS exceeded consensus, supported by 15% Global Business Solutions growth and continued mid-market momentum, while Credit Karma’s 9% growth missed expectations and drove most of the FY27 revenue guidance reduction. Also agreed to sell email marketing platform Mailchimp to BSP for about $3.68 billion, five years after acquiring it for nearly three times more.
  • NVDA -5%; on track to decline for a 7th straight day (and 7th straight weekly decline) and is now -$100 (or -42%) from its 52 week high of $243.37 on October 6th.
  • ROST -2%; reported a Q3 earnings beat and raised FY EPS guidance while comp sales were strong throughout the quarter before slowing at the end of October due to unseasonably warm weather (expects Q4 comparable sales growth of 4%-5%, versus 8% in Q3 and 9% in the year-ago holiday qtr); cuts Q4 EPS forecast by 1 cent at both ends to $2.16-$2.25 while raised FY guidance for EPS to $8.15-8.24 (was $8.01-8.17).
  • SVRA -16%; after saying the FDA said it will not meet the action date of November 22 for its experimental drug molgramostim, an inhalation solution for the treatment of autoimmune PAP, a rare lung disease characterized by the abnormal build-up. FDA's review is ongoing, and no revised date has been provided by the agency.
  • XPEV -8%; was downgraded to Hold from Buy and cut PT to $10.10 from $17 at HSBC and cut 2026-28 volume estimates 1%-7% as older models weaken faster than expected, stating that it previously underestimated the pace of sales declines across older models

Closing Recap

Thursday, November 19, 2026

Index

Up/Down

%

Last

DJ Industrials

-1,100.40

2.19%

49,097

S&P 500

-147.74

2.02%

7,175

Nasdaq

-550.69

2.25%

23,879

Russell 2000

-59.17

2.18%

2,655

 

 

 

 

 

 

 

 

 

US equities enjoyed a strong overnight bounce but were already giving some back in pre-market trading, so perhaps the conviction was weak.  More hawkish Fed commentary yesterday definitely did not help, and more speakers were upcoming today.  Morning jobless claims were a bit higher than forecast and the Philly Fed data was way below expectations but those weren’t market moving. In Sentiment today, the bull-bear spread in the American Association of Individual Investors (AAII) weekly survey was -8.9% vs -20.6% last week with bulls rising to 33.3% to from 30.8% and bears falling to 42.2% from 51.4%. Perhaps value-seekers are emerging.  Meanwhile today’s Fear & Greed Index hit 24 (Extreme Fear), down from last week’s 40 (Fear), but better than last month’s 19 (Extreme Fear).

 

A rapid fade in the first hour of trading saw early breadth favoring decliners by 6:5 as small caps underperformed with IWM (-0.42%) versus SPY (+0.29%) and QQQ (+1.00%). SPY breadth favored decliners by 5:2 while QQQ breadth favored decliners by 9:7 as a handful of mega caps really were about the only reason indices held green. Technology (+1.62%), Energy (-0.10%) and Industrials (-0.33%) were outperformers among S&P sector ETFs, while Utilities (-1.14%), Health Care (-1.31%) and Consumer Staples (-1.66%) paced the underperformers with only 1 sector gaining, and supporting the indices, versus 10 declining.

 

Heading into the final hour of trading, markets were showing us another solidly red day as Fed speakers did nothing to lift spirits and the Anthropic IPO euphoria faded pretty quickly.  Breadth had deteriorated to about 4:1 decliners over advancers with QQQ breadth more than 7:1 and SPY breadth about 12:1 also favoring decliners. Sector performance had rolled with all 11 in the red led lower by Consumer Discretionary, Communications and Health Care all down more than 2%. Energy was the best performer at -0.63%, followed by Utilities at -1.14%.  The Santa rally can't come soon enough.

 

Silver lining? @BenKizemchuk noted on X, “Since 1975, there have been just 57 occasions where the S&P 500 closed lower for six straight sessions. The average path afterward was positive across every forward time horizon studied, with gains improving from +0.6% after one week to +2.6% after roughly six weeks. The index was higher 68%-70% of the time after 10-25 trading days. While not a timing signal, the historical evidence suggests persistent selling pressure tends to be associated with seller exhaustion more often than the start of larger declines.”

Economic Data

  • Weekly Jobless Claims climbed to 203,000 from 202,000 prior and above consensus 197,000; the 4-week moving average climbed to 197,750 from 195,750 prior week (previous 195,250); continued claims climbed to 1.763M (consensus. 1.710M) from 1.693M prior week.
  • Philadelphia Fed business conditions November falls to 6.3 from 20.9 in October and below consensus 20.0; prices paid index November jumps to 58.2 vs October 43.2; new orders index November -0.4 vs October 4.3; employment index November 11.6 vs October 9.1; six-month business conditions November 33.6 vs October 33.0 and Philadelphia Fed six-month capital expenditures outlook November 18.9 vs October 34.9.

Commodities, Currencies & Treasuries

  • Gold followed yesterday’s roll with a small overnight decline then continued to slip intraday.  More hawkish recent commentary by Fed speakers has only added to concerns about rising rates into next year with resulting increases in both the Dollar and yields weighing on precious metals. December gold settled -$56.40/oz, or -1.51%, at $3,685.50 while December Silver fell harder than gold, falling -$1.07, or 2.4%, to $43.99 an ounce after dipping to $43.88, its lowest since September 2025.
  • WTI crude futures were up small overnight following a modest pullback yesterday. Impactful news was sparse, but headlines did indicate Iran specified IAEA nuclear inspections would never return to what they were prior to attacks and, separately, Houthi attacks continued with Saudi civil defense saying a tower in Riyadh financial center had been hit but no injuries were reported. January WTI crude settled +$0.13/bbl, or +0.16%, at $82.44.
  • Bitcoin falls to fresh 4-month low around $61,880 late day. The dollar edged up against a basket of peers on Thursday, extending its recent rally, as risk sentiment took a beating and Anthropic's super-sized IPO failed to revive fading enthusiasm for artificial intelligence. The recent dollar rally, which started on November 10 when hotter-than-expected US inflation data boosted expectations of Fed tightening, found support on Thursday as riskier currencies sold off. Treasury yields managed to edge lower, however.

 

Macro

Up/Down

Last

WTI Crude

0.13

82.44

Brent

0.03

91.98

Gold

-56.40

3,685.50

EUR/USD

0.0000

1.0978

JPY/USD

0.42

159.70

10-Year Note

-0.014

5.051%

 

Sector News Breakdown

Retail, Consumer Staples & Restaurants:

  • Discount/Broadline retail: Dow component WMT reported Q3 revs grew 5.2% y/y to $188.8B, topping ests $187.27B and comps +2.9% vs. +2.6% in Q2; said strongest growth came from its e-commerce, membership and advertising businesses as global eCommerce sales grew by 17% and 23% in the U.S. Its U.S. advertising business was up 37%; raised FY sales growth to 4.9%-5.2%, from previous range of 4% to 5% and raises yearly EPS outlook to $2.84-$2.89, from prior $2.80-$2.87.
  • Online retailers: BABA Q3 revenue reaches 271.52 billion yuan, topping estimates as demand for its AI cloud services surged, while investment gains helped more than triple reported profit; Excluding investment gains and other items, non-GAAP net income leapt 92% to 19.9 billion yuan; Temu owner PDD shares rose after Q3 adj profit topped consensus as the company cut sales and marketing spending; adj net profit was 31 billion yuan ($4.65 billion) for Q3 vs. consensus estimate of 28.03 billion yuan and revs of 108.3 billion yuan ($16.25 billion) topped consensus of 115.97 billion yuan.
  • Specialty retailers: BBWI posted Q3 sales $1.58B vs. est. $1.55B but forecasts wider-than-expected decline in Q4 net sales amid early stages of turnaround; now sees Q4 net sales to decline between 2%-5.5%, compared with estimates of a -2.7% drop and narrows year sales view to decline between 3.4% and 2.1%, from its previous forecast of a 4% to 2.5% fall; sees year EPS $3.09-$3.29 vs. prior view $3.13-$3.33.
  • Footwear & Apparel retail: DKS was downgraded to Sell from Hold and cut tgt to $120 at Williams Trading ahead of earnings saying the company's FY27 outlook is about to get worse as weak back-to-school traffic and elevated inventory levels at Foot Locker will result in Dick's either missing or coming in at the low end.
  • Home furnishing sector: WSM shares fell after Q3 EPS reported in-line and slight sales miss of $1.99B vs. estimates $2.0B while reiterates annual comparable sales growth forecast in the range of 4% to 6.5%, and comp sales up 4%-6.5%, but says will provide fiscal 2027 forecast in March.
  • Restaurant sector: RRGB posted a wider than expected Q3 EPS loss (-$0.54) vs. est. loss (-$0.34); Q3 revs fell -12% y/y to  $232.1M vs. est. $253.6M; Q3 FY26 net loss widened 15% y/y to -$21.19M; chain refranchised 108 restaurants during the quarter for approximately $89.4M in cash; guides Q4 adj Ebitda about $6M
  • Auto parts retailers (AZO, AAP, ORLY) were weaker early after UBER announced a partnership with AutoParts.com that brings auto parts to the Uber Eats platform. The deal allows customers to order parts from nearly 7,000 locations nationwide for on-demand or scheduled delivery. The partnership expands Uber's retail marketplace into the automotive category, raising concerns that traditional auto parts chains could face increased competition as consumers gain another convenient option for obtaining parts quickly.

Energy

  • Heavy Equipment and Utility: BE was upgraded from Market Perform to Outperform at BMO Capital and lowered tgt from $260 to $230 saying a non-deal roadshow with CFO and VP of IR reinforced confidence in commercial traction and execution. After the share-price pullback, BMO sees upside to 2027 consensus.
  • Energy equipment: HP posted Q4 adj EPS $0.36 vs. est. $0.27; Q4 revs $1.1B vs. est. $1.073B; said expect numerous growth opportunities across key markets to drive stronger overall direct margins compared to FY26; guides FY capex view $320M-$360M; expect to operate average 19 rigs through Q1, with potential for further activity reductions over course of year.

Financials

  • Insurance sector: RGA was upgraded to Buy and raise PT to $325 from $236 at UBS as believe the market is overlooking the combination of 1) upside from continued mortality improvements (~5 points of upside to 2027E), and 2) upside from the EQH deal accretion (~2 points of upside). UNM was upgraded from Neutral to Buy at UBS and raise tgt to $111 as believes the market is underappreciating ~8% potential upside to 2027 cons. EPS from improving mortality. At the same time, risk transfer has significantly reduced LTC risk, with ~70% of the block now in the lower-risk group category. ALL announces October estimated catastrophe losses of $232M, or $184M after-tax.
  • Insurance brokers: Wells Fargo with several changes as they downgraded AJG to Equal Weight from Overweight (sees slowing brokerage organic growth for Arthur J. Gallagher), AON also cut to Equal Weight (as expects "noise and volatility" in Aon's price); while upgraded BRO to Overweight from Equal Weight (tgt to $82 from $68) and MRSH upgraded to Overweight (tgt to $235 from $197), saying brokers remain its favored sub-sector, with WTW their top idea. Notes The BRO has a "low bar" for its organic growth heading into 2027, given the weakness seen over the past couple of years; sees earnings upside for Marsh in 2027 from the AltamarCAM and Wilshire acquisitions.

Biotech & Pharma:

  • BHVN price target raised to $35 from $14 at JPMorgan and stays Overweight rated citing the FDA accepting for review the new drug application resubmission for Vyglxia in spinocerebellar ataxia. JPMorgan believes there is the potential for upside from current share levels and remains positive.
  • INSM shares jumped after Bloomberg reported SNY is noted to weigh takeover of US drugmaker Insmed.
  • NVS set a target of annual sales growth of 5% through 2031, which is lower than a 5% to 6% annual sales growth range it set last year for 2025-2030. By 2031, breast cancer drug Kisqali and Cosentyx for autoimmune diseases, two of Novartis' best-selling medicines, will face competition from cheaper rivals.
  • SLS shares tumbled after selling 11.5M shares of stock at $13, a 27.6% discount to last sale. SLS shares surged 156% to finish at $19.15 on Tues its blood cancer vaccine, galinpepimut-S, extends survival in late-stage trial.

Healthcare Services & MedTech movers:

  • Managed care: the sector was pummeled the last two days (ELV, UNH, CI, HUM, CNC, MOH, CVS). Goldman Sachs said today they see the sharp sector selloff following the Blue Sweep and CRUSH/RADV proposal as reflecting greater policy uncertainty rather than a comparable deterioration in earnings fundamentals. The firm sees the $9bn annual RADV recovery assumption as difficult to reconcile with current MA profitability and improving MA improper-payment rates, while Medicaid names benefit near term from delayed work-requirement pressure. View the pullback as a buying opportunity in UNH with CVS also offering significant upside from current levels.

Industrials & Materials

  • E&C sector: PRIM was downgraded from Buy to Hold at Jefferies and PT lowered from $99 to $66 saying another reset in Renewables drives negative estimate revisions, only partly offset by Gas Generation, Power Delivery, and PayneCrest. LIN was upgraded from Hold to Buy at Kepler and PT raised from $490 to $601 saying Lincare weighed on margins in Q2 and Q3. Kepler expects restructuring and an eventual disposal to address the drag, with current investments supporting future earnings growth.
  • Aerospace & Satellite sector: ASTS was upgraded from Neutral to Buy at B Riley and maintains $48 tgt noting shares have fallen 55% since the firms downgrade on 10/1, versus a 3.3% decline in the Russell 2000 and believes the selloff prices in much of the risk around capital commitments, Constellation deployment.

Materials, Metals & Mining

  • Metals & Mining sector: UBS noted key metals including copper, gold, aluminium & Silver are down 8 15% over the last 3 weeks, with copper/aluminium recently breaking key technical support levels triggering further long liquidation. The firm says the unwind of the Ai trade, US mid-terms & US CPI print causing a repricing of the Fed have acted as key catalysts. UBS believes global macro events triggering positioning reset (vs stale longs in copper) are largely responsible for the correction vs clear evidence of material demand weakness. No real bounce in precious metals this morning with gold/silver miners sliding.
  • Copper yesterday fell ~6% on the LME to US$12,471/t, its lowest since April, as investors unwound bullish positions built around AI-related demand and potential US refined copper tariffs. The sell-off accelerated after Stan Druckenmiller turned bearish, and narrowing COMEX-LME spreads point to fading tariff expectations. Physical tightness in China remains acute, with the Yangshan import premium at a record US$360/t (from below US$100/t in Sept) and SHFE inventories down 18% w/w to 27.6kt, their lowest since December 2023, BMO Capital noted. The selloff was exacerbated by copper's slide through key support levels, which triggered further selling by funds that use algorithms and technical signals for trading, traders said.
  • Paper & Packaging sector: IP was downgraded to Hold from Buy at Argus saying the company has a strong record in the industry, but its earnings have been hurt by higher input costs, tariff uncertainty, and a soft demand environment, and its recent DS Smith acquisition is underperforming and providing less value than the market initially anticipated.

AI, Semis & Data Centers

  • Anthropic (ANT) priced its initial public offering at $83 a share, above its $70 to $78 target range, and then opened at $111.50 per shares before pulling back. The offering was increased in size, the person said, in one of the largest stock-market IPOs on record and the first by a major frontier AI model developer,
  • AMBA shares jumped on a report that the company may be in the final stages of a deal to be sold to NXPI, per Betaville. Betaville reported late last month that Ambarella was speculated to be in exclusive talks with NXPI. https://tinyurl.com/khpbtctd
  • KLIC Q4 Adjusted EPS $1.52 vs. est. $1.43 (beat), revenue $410.3Mm vs. est. $376.8Mm (beat), and gross margin 47.8%; sees Q1 FY27 adjusted EPS $1.65 plus or minus 10% vs est $1.43 and revenue $410Mm plus or minus $20Mm vs est $373.3Mm.
  • TSM and Samsung suspend some chip shipments to Chinese customers, the Financial Times reported; both have halted deliveries of certain processors to Chinese customers while they apply for licenses from the U.S. Commerce Department.

Internet, Hardware & Software movers:

  • Security software sector: PANW shares jumped on results as delivered a strong Q1 print, punctuated by NGS ARR (+66%-Y/Y), Product Revenue (+37%-Y/Y), Total Revenue (+39%-Y/Y), and EPS above consensus; saw broad-based traction across the platform (Network/AI Security, Cortex, Idira); Q2 guidance was above expectations and announced the $4.5B acquisition of Applied Compute, which helps customers train, adapt, and deploy open-source and open-weight Ai models in the Cloud or in sovereign environments.
  • SaaS/Cloud software: MDB was upgraded to Buy and upped tgt to $450 at UBS saying checks pointed to steady demand with better than expected customer and partner growth outlooks indicating no signs of disruption from recent management turnover, which it thinks supports durable 20%+ total revenue growth and 25%+ Atlas revenue growth over the coming years.
  • Storage & Hardware sector: BOX was upgraded from Neutral to Buy at UBS and raise tgt from $37 to $55 saying checks suggest Ai-related demand can sustain faster growth beyond the initial enterprise-plan upgrade Cycle as customers use Box for more valuable document and content workflows. Everpure Inc. (P) posted better results as Q3 revs $1.5B top  est. $1.335B and Q3 adj Operating Income $345M vs. est. $273.7M; guides FY rev outlook $5.2B-$5.21B vs. consensus estimates of $5.06B and raises FY27 adjusted operating income view to $1.08B-$1.09B from $940M-$960M.
  • Online Services: NTES shares fell after posts adj. EPS of 14.21 yuan ($2.13) compared to estimate of 16.11 yuan ($2.42); Q3 revenue of 27.9B yuan ($4.2B), missed analysts' consensus of RMB 30.2B yuan ($4.53B); said results weighed down by a fall in revenue generated by NetEase-owned Education tech company Youdao.
  • Optical sector: COHR authorizes share repurchase program up to $2B.

Not offered or endorsed by Regal Securities

Street Recommendations

Friday, November 20, 2026

ARGUS

  • NFG Argus downgraded National Fuel to Hold from Buy.
  • BRK Argus downgraded Berkshire Hathaway to Hold from Buy. The firm notes that the stock has recently surpassed its $550 price target on significant company buybacks and as an anti-AI trade, even though it continues to have a positive view of Berkshire Hathaway's conglomerate nature, the analyst tells investors in a research note. Berkshire's equity portfolio also has had a value tilt historically, the firm added.

B. RILEY

  • PRAX B. Riley initiated coverage of Praxis Precision with a Buy rating and $713 price target, over two-times current share levels. Within 10 weeks, Praxis could evolve from clinical to commercial stage with two potential blockbuster approvals 30 days apart, the analyst tells investors in a research note. Riley sees approvals of relutrigine in epileptic encephalopathies by the December 27 FDA action and ulixacaltamide in essential tremor January 29, 2027, action date. Essential tremor the larger opportunity, drives conviction in the shares as it is the most common U.S. movement disorder, 10-times more prevalent than Parkinson's disease, yet neglected by drug developers for decades, contends Riley.

BARCLAYS

  • BABA Barclays lowered the firm's price target on Alibaba to $155 from $200 and keeps an Overweight rating on the shares. The company's AI compute capacity build ambition was lowered post the latest U.S. governemnt compute restrictions against Chinese companies, the analyst tells investors in a research note. The firm says this could be a "blessing in disguise."
  • BRBR Barclays raised the firm's price target on BellRing Brands to $16 from $12 and keeps an Overweight rating on the shares. The company is "stepping up work" on costs to manage inflation and fund brand investment while setting a better foundation around innovation, insights, promotional returns, and incremental channel opportunities, the analyst tells investors in a research note.
  • ESTC Barclays lowered the firm's price target on Elastic to $102 from $118 and keeps an Overweight rating on the shares post the fiscal Q2 report. The company's "strong" cloud consumption helped it beat across the board, the analyst tells investors in a research note. The firm says a Q4-weighted self-managed renewals and a more cautious stance on Europe drove some guidance prudence for the second half of the year, though Elastic's broad narrative remains unchanged.
  • INTU Barclays lowered the firm's price target on Intuit to $385 from $408 and keeps an Overweight rating on the shares following the fiscal Q1 report. Near term, there will be ongoing headwinds to Intuit's shares as Credit Karma is "now also a major segment that needs fixing," the analyst tells investors in a research note. Barclays is "not sure there is a short term come back here" but says the shares are "cheap."
  • KEYS Barclays raised the firm's price target on Keysight Technologies to $439 from $429 and keeps an Overweight rating on the shares. The company's fiscal Q4 results beat expectations, with "very strong" AI infrastructure demand and expanding use cases and opportunity broadening across customers, the analyst tells investors in a research note.
  • WMG Barclays raised the firm's price target on Warner Music to $35 from $31 and keeps an Equal Weight rating on the shares. The company's operating visibility remains high heading into 2027 with guidance on streaming revenue growth and margins continuing to have upside, the analyst tells investors in a research note.

BERNSTEIN

  • WMG Bernstein analyst Ian Moore raised the firm's price target on Warner Music to $40 from $39 and keeps an Outperform rating on the shares. The firm notes Warner Music closed FY26 with its strongest subscription streaming print of the year and guided FY27 in-line with its long-term targets adjusted for inorganic contributions. Bernstein continues to see that guide as a floor.
  • ABNB Bernstein raised the firm's price target on Airbnb to $234 from $217 and keeps an Outperform rating on the shares. The firm notes Airbnb delivered 19% revenue growth and guided to 16%-18% growth in Q4. Airbnb has been seemingly immune to headwinds, with strong growth set to continue, driven by a deep pipeline of features.
  • BKNG Bernstein analyst Richard Clarke lowered the firm's price target on Booking Holdings to $172 from $188 and keeps a Market Perform rating on the shares. The firm notes Booking delivered growth but guided to a deceleration in Q4. Booking could explain its weaker growth, suffering from geopolitical headwinds in the Middle East and Europe.
  • EXPE Bernstein lowered the firm's price target on Expedia to $261 from $310 and keeps a Market Perform rating on the shares. The firm says strength in quarter growth at Expedia was overshadowed by the guided deceleration in their B2B segment as it begins to lap strong performance and declining economics.

BOFA

  • BBY BofA analyst Christopher Nardone raised the firm's price target on Best Buy to $83 from $80 and keeps an Underperform rating on the shares. The firm sees downside risk to calendar 2027 estimates as rising memory costs will likely drive promotions, but thinks the comp momentum from Q2 will continue in the second half of 2026 and raised its Q3 and Q4 comp growth estimates to 3%, or the high end of guidance, the analyst tells investors in a preview. To reflect higher revenue estimates, the firm is raising FY27 and FY28 EPS estimates by 1% and 2%, respectively, to $6.85 and $6.87.
  • ROAD BofA lowered the firm's price target on Construction Partners to $112 from $139 and keeps a Buy rating on the shares. Construction Partners reported a "disappointing" fiscal Q4, though that was partly expected, the analyst tells investors. A lower multiple is warranted given cost inflation and funding uncertainty post the midterms, though Construction Partners is "more stable than the market implies," the analyst added.
  • INTU BofA lowered the firm's price target on Intuit to $310 from $360 and keeps a Neutral rating on the shares. Intuit cut FY27 revenue growth guidance to 8.3% year-over-year from 9.1%, despite Q1 revenue growth beating expectations, the analyst tells investors. The firm, which reduced its estimates, sees both cyclical and secular pressures facing Intuit.
  • ESTC BofA lowered the firm's price target on Elastic to $100 from $114 and keeps a Neutral rating on the shares. The company reported "good" fiscal Q2 results and modestly raised the FY27 constant currency guidance by roughly the beat, but the firm thinks the risk/reward is balanced until there is clearer evidence of whether SLS growth can sustainably exceed 20%-plus, the analyst tells investors.
  • HIMS BofA analyst Allen Lutz lowered the firm's price target on Hims & Hers to $21 from $26 and keeps a Neutral rating on the shares after the Kentucky Board of Pharmacy voted to prohibit pharmacies from compounding the six peptides that were recently enabled for compounding under the HHS enforcement-discretion policy. The news is "a somewhat negative development" as the action likely removes the state's patient pool from Hims' near-term addressable peptide market, but "more importantly" also signals potential roadblocks to a broader rollout if other states decline to permit compounding, the analyst tells investors.
  • KEYS BofA lowered the firm's price target on Keysight Technologies to $375 from $405 and keeps a Buy rating on the shares. Keysight ended the year with pipeline at an all-time high, notes the analyst, who sees no signs of an order peak given the company's well-diversified demand. However, the firm lowered its price target to reflect lower peer multiples.
  • SNOW BofA lowered the firm's price target on Snowflake to $400 from $470 and keeps a Buy rating on the shares ahead of the company's fiscal Q3 results due on Wednesday, December 2. The "key debate" is if Product revenue growth can clear elevated expectations, says the analyst, who thinks the bar is 43%, implying a 4% dollar beat versus the midpoint of guidance. While a beat of less than 4% could create initial volatility, the firm believes weakness would be bought unless the beat falls below 2% or the fiscal Q4 outlook points to growth meaningfully below 37%, the analyst added.
  • WMT BofA raised the firm's price target on Walmart to $141 from $139 and keeps a Buy rating on the shares. Walmart continues to gain share, notes the analyst, who sees the company's strengthening value, convenience and assortment proposition supporting further share gains into holiday and beyond.
  • WMG BofA raised the firm's price target on Warner Music to $35 from $30 and keeps a Neutral rating on the shares after fiscal Q4 results beat the firm's revenue and adjusted OIBDA projections in what the analyst calls a "solid end of the year." The firm raised FY27 estimates following Q4 results, but continues to view the risk/reward as balanced at current levels.
  • BBWI BofA lowered the firm's price target on Bath & Body Works to $25 from $30 and keeps a Buy rating on the shares. The firm is lowering its FY27 EPS estimate by 13% to $2.60 to include Canadian tariff pressure and input cost pressures, but thinks management is taking the right steps to turn the brand and expects multiple expansion as Bath & Body inflects sales and stabilizes margins, the analyst tells investors.

BTIG

  • BILL BTIG downgraded Bill to Neutral from Buy without a price target after the company entered into a definitive agreement to be acquired for $63.25 per share in cash. BTIG expects the deal to close. The firm is surprised the deal was not struck at a slightly higher price.

CANACCORD

  • VFF Canaccord analyst Kenric Tyghe initiated coverage of Village Farms with a Buy rating and $5.50 price target. The firm says the market is pricing Village Farms as a Canadian licensed producer with an export side business. However, Canaccord thinks "it is the reverse." Village has the world's largest European Union's pharmaceutical good manufacturing practice certified cannabis facility, a "scarce" Dutch license, and a net cash balance sheet that makes it a supplier that European medical markets cannot easily replace, the analyst tells investors in a research note.

CANTOR FITZGERALD

  • NKE Cantor Fitzgerald analyst John Kernan lowered the firm's price target on Nike to $33 from $38 and keeps a Neutral rating on the shares. Nike's Investor Day reinforced management's confidence and strong athlete connections, but the turnaround strategy will require patience before results materialize, the analyst tells investors in a research note.
  • ROST Cantor Fitzgerald analyst John Kernan lowered the firm's price target on Ross Stores to $264 from $276 and keeps an Overweight rating on the shares. Ross Stores delivered 8% comps and an EPS beat, with 70 basis points of gross and EBIT margin expansion, while 91% new-store productivity and transaction-led growth highlight continued customer demand and expansion potential, the analyst tells investors in a research note.
  • ESTC Cantor Fitzgerald lowered the firm's price target on Elastic to $75 from $100 and keeps a Neutral rating on the shares. Elastic delivered a strong Q2 on accelerating Cloud growth in Security and Search, but cautious Q3 guidance, macro uncertainty and flat Observability growth temper confidence until subscription growth and retention improve, the analyst tells investors in a research note.
  • POWL Cantor Fitzgerald analyst Manish Somaiya raised the firm's price target on Powell to $178 from $135 and keeps a Neutral rating on the shares. Powell's backlog supports sustained margin improvement, while rising configure-to-order volumes could boost factory throughput, with near-term startup inefficiencies viewed as temporary rather than structural margin risks, the analyst tells investors in a research note.

CITI

  • BABA Citi lowered the firm's price target on Alibaba to $160 from $193 and keeps a Buy rating on the shares. The firm views Alibaba's revised cloud outlook as "pragmatic" given the evolving compute export restrictions. The outlook does not change the company's long-term AI ambitions, the analyst tells investors in a research note. Citi cites the broader sector de-rating for the target cut.
  • NXT Citi lowered the firm's price target on Nextpower to $124 from $126 and keeps a Buy rating on the shares. The firm updated the company's model following its capital markets day. Nextpower's fiscal 2030 margins were largely in line with Citi's below consensus forecast, but the lower fiscal 2028 margin outlook was an "unexpected negative," the analyst tells investors in a research note. Citi cites the reduced margin outlook for the target cut.
  • WSM Citi lowered the firm's price target on Williams-Sonoma to $245 from $275 and keeps a Neutral rating on the shares. The company missed high expectations in Q3, the analyst tells investors in a research note. Citi says Williams-Sonoma report lacked upside while the shares were trading near peak valuations.
  • KEYS Citi analyst Atif Malik lowered the firm's price target on Keysight Technologies to $345 from $400 and keeps a Buy rating on the shares. The company reported better than expected October quarter results on broad-based momentum, the analyst tells investors in a research note. Citi cites lower market multiples for target target cut.

DA DAVIDSON

  • NBHC DA Davidson downgraded National Bank to Neutral from Buy with a price target of $38, down from $43. The firm sees slipping traction with 2UniFi, credit and EPS expectations as potential headwinds as "each area has tilted unfavorably," the analyst tells investors.
  • COFS DA Davidson downgraded ChoiceOne Financial to Neutral from Buy with a price target of $38, down from $40. The firm says the bank's valuation has aught up to the its performance. DA believes the drivers behind its Buy thesis have largely played out. ChoiceOne's net interest income growth s set to slow as deal benefits wane and earnings growth projected to trail peers, the analyst tells investors in a research note.
  • BMRC DA Davidson analyst Jeff Rulis downgraded Bank of Marin to Neutral from Buy with a price target of $28, down from $34. Expectations are rising post credit recovery, though the bank's growth outlook is "muted" and a takeout looks "less likely," the analyst tells investors. The firm's projections suggest the bank will be "stuck in a low single digit loan growth phase" through 2027, the analyst added.
  • BANR DA Davidson upgraded Banner Corp. to Buy from Neutral with a price target of $82, up from $76. The firm's prior valuation assumptions were too low considering Banner's higher relative net interest income and EPS growth projections, "superior operational consistency" and the potential for a takeout premium "down the road," the analyst tells investors.
  • EBMT DA Davidson analyst Jeff Rulis upgraded Eagle Bancorp to Buy from Neutral with a price target of $24, up from $23. The firm views the bank's growth in Q3 as "game changing." Eagle has a "zero cost option" on mortgage upside and a "substantial" operating leverage opportunity, the analyst tells investors in a research note. DA says its prior valuation assumptions were too low.

GOLDMAN SACHS

  • STC Goldman Sachs initiated coverage of Stewart with a Neutral rating and $49 price target, which indicates 14% upside. The company is positioned for market share and margin expansion into 2028 and over the medium-term as its business gains scale, the analyst tells investors in a research note. However, mortgage market activity is "lackluster currently," the analyst tells investors in a research note. Goldman estimates low-single-digit revenue growth for Stewart in 2027.
  • HESM Goldman Sachs analyst John Mackay lowered the firm's price target on Hess Midstream LP to $29 from $33 and keeps a Sell rating on the shares. Hess slightly beat expectations as stronger margins offset softer volumes, but uncertainty around post-restructuring operations and financials remains, with further disclosures needed to assess potential value despite its roughly 10% dividend yield, the analyst tells investors in a research note.
  • ESTC Goldman Sachs lowered the firm's price target on Elastic to $90 from $105 and keeps a Neutral rating on the shares. Elastic's Q2 showed progress, but sustained Cloud momentum and stronger Observability growth are needed to confirm that Sales-Led Subscription Revenue acceleration is durable, the analyst tells investors in a research note.

GUGGENHEIM

  • TYRA Guggenheim assumed coverage of Tyra Biosciences with a Buy rating and a price target of $55, up from $54. Dabogratinib is "poised to break the vicious cycle of repeated urethral administrations" from standard of care in patients with non-muscle invasive bladder cancer and upper tract urothelial carcinoma harboring an activating FGFR3 mutation, the analyst tells investors.
  • WWD Guggenheim raised the firm's price target on Woodward to $410 from $404 and keeps a Buy rating on the shares. While the company is positioned to drive the top-line due to "robust demand signals," the firm thinks investors should focus on how initiatives to boost operational efficiency are progressing next year, the analyst says in a post-earnings note.

HSBC

  • XPEV HSBC analyst Yuqian Ding downgraded XPeng to Hold from Buy with a $10.10 price target.

JEFFERIES

  • BILL Jefferies analyst Samad Samana downgraded Bill to Hold from Buy with a price target of $63.25, up from $62, after the company agreed to be acquired by TPG in partnership with Corpay for $63.25 per share. The firm says "risk-off action" of the last week likely weighed on the takeout price. Jefferies see a low likelihood of another bidding emerging.
  • FTS Jefferies analyst Julien Dumoulin-Smith downgraded Fortis to Underperform from Hold with a price target of C$72, up from C$70. The firm says "elevated risk" to formula rates longer term in Arizona from the expected anti-annual rate adjustment mechanism commissioner majority will challenge the company's "ten-year-high" 28% valuation premium. Jefferies cites on valuation and the Arizona regulatory update for the downgrade.
  • ESTC Jefferies analyst Brent Thill lowered the firm's price target on Elastic to $100 from $110 and keeps a Buy rating on the shares. The firm views the company's' fiscal Q2 report as a "clean beat" with revenue growth accelerating. Jefferies believes Elastic's valuation already reflects execution risk and remains constructive on the company's long-term setup as the AI context layer.
  • INTU Jefferies lowered the firm's price target on Intuit to $445 from $500 and keeps a Buy rating on the shares. The firm views the company's fiscal Q1 report as "more eventful than expected," with Mailchimp divested for a loss and Credit Karma facing macro and AI headwinds. Jefferies believes Intuit needs to improve overall execution to regain investor credibility. It sees an attractive risk/reward at current share levels.

JPMORGAN

  • BOKF JPMorgan initiated coverage of BOK Financial with a Neutral rating and $145 price target. BOK has grown into a $54B asset size bank that serves clients across eight states in the South and the Southwest through 116 branches, the analyst tells investors in a research note. The firm cites the stock's valuation for the Neutral rating.
  • MSGR JPMorgan initiated coverage of MSG Rangers with an Overweight rating and $310 price target. The company offers investors pure-play ownership in the New York Rangers, one of the NHL's original six franchises and highest revenue clubs, the analyst tells investors in a research note. JPMorgan says the shares trade at an "attractive" 30% discount to private-market value estimates, which it attributes to the lack of comparable transactions in major markets. It is bullish on professional team valuations generally.
  • BILL JPMorgan downgraded Bill (BILL) to Neutral from Overweight with a price target of $63, up from $60, after the company entered into a definitive agreement to be acquired by TPG in partnership with Corpay (CPAY) for $63.25 per share. The deal structure "smartly mirrors" Corpay's 2025 investment in AvidXchange alongside TPG, the analyst tells investors in a research note. JPMorgan views private ownership as a positive for Bill. It ultimately expects the deal to close.
  • VVV JPMorgan analyst Jeffrey Zekauskas downgraded Valvoline to Underweight from Neutral with an unchanged price target of $35. The firm cites valuation for the downgrade following the fiscal Q4 report. JPMorgan expects Valvoline to throw off 1%-2% of its share price in free cash flow in fiscal 2027, which it views as relatively low. Assuming maintenance capital expenditures only, Valvoline's free cash flow yield should be about 5%, the analyst tells investors in a research note.
  • EMN JPMorgan downgraded Eastman Chemical to Underweight from Neutral with a price target of $62, down from $65. The company's larger markets are not growing, and its spreads are under pressure, the analyst tells investors in a research note. The firm says global auto production is declining, the domestic housing market is battling high interest rates, and Eastman's commodity businesses are experiencing narrowed spreads in propane and propylene. It will be difficult for Eastman "to keep up with the market under these conditions," contends JPMorgan.
  • CE JPMorgan raised the firm's price target on Celanese to $79 from $77 and keeps an Overweight rating on the shares. Acetyl chain prices are somewhat stronger than expected, the analyst tells investors in a research note.
  • PRAX JPMorgan analyst Tessa Romero raised the firm's price target on Praxis Precision to $725 from $700 and keeps an Overweight rating on the shares. JPMorgan also added Praxis to its Analyst Focus List as a growth idea. The firm sees ulixacaltamide as an "approvable asset" and has increased conviction in the approval for essential tremor. Praxis noted last week that late-cycle FDA meeting discussions focused primarily on labeling and expressed high conviction around an approval, the analyst tells investors in a research note. JPMorgan's valuation assumes $9B of unadjusted peak U.S. sales in essential tremor. It believes this could prove conservative.

KEYBANC

  • WMT KeyBanc raised the firm's price target on Walmart to $145 from $135 and keeps an Overweight rating on the shares. The firm notes Q3 results were solid, as comparable sales and share gains accelerated while digital and emerging businesses remain strong. Trends bode well for the holidays and Q4. Walmart raised 2026 guidance and sees 2027 as another algo year, adds KeyBanc.
  • BILL KeyBanc analyst Andrew Schmidt downgraded Bill to Sector Weight from Overweight without a price target after the company entered into a definitive agreement to be acquired for $63.25 per share in cash.

MACQUARIE

  • PDD Macquarie upgraded PDD Holdings to Outperform from Neutral with a price target of $106, up from $98, following the Q3 report. The company's Temu is showing clearer signs of approaching profitability, the analyst tells investors in a research note. The firm expects Temu to maintain a "prudent marketing strategy, which could support an improved earnings outlook." Macquarie believes PDD's "depressed multiple and strong cash position" provide downside support for the shares.

MIZUHO

  • BABA Mizuho raised the firm's price target on Alibaba to $205 from $200 and keeps an Outperform rating on the shares. The firm says the company's earnings report reinforces the thesis that AI cloud is becoming Alibaba's key growth and earnings driver.
  • AXS Mizuho raised the firm's price target on Axis Capital to $129 from $123 and keeps an Outperform rating on the shares. The firm adjusted targets in the property and casualty group following the Q3 earnings reports. The results point to P&C earnings further shifting from underwriting to net interest income and buybacks, the analyst tells investors in a research note.
  • AIG Mizuho analyst Yaron Kinar raised the firm's price target on AIG to $90 from $89 and keeps a Neutral rating on the shares. The firm adjusted targets in the property and casualty group following the Q3 earnings reports. The results point to P&C earnings further shifting from underwriting to net interest income and buybacks, the analyst tells investors in a research note.
  • ACGL Mizuho raised the firm's price target on Arch Capital to $109 from $106 and keeps a Neutral rating on the shares. The firm adjusted targets in the property and casualty group following the Q3 earnings reports. The results point to P&C earnings further shifting from underwriting to net interest income and buybacks, the analyst tells investors in a research note.
  • CB Mizuho raised the firm's price target on Chubb to $368 from $350 and keeps a Neutral rating on the shares. The firm adjusted targets in the property and casualty group following the Q3 earnings reports. The results point to P&C earnings further shifting from underwriting to net interest income and buybacks, the analyst tells investors in a research note.

MORGAN STANLEY

  • INTU Morgan Stanley lowered the firm's price target on Intuit to $310 from $315 and keeps an Equal Weight rating on the shares. Strong EPS execution was overshadowed by a Credit Karma-led FY27 revenue cut and weak Q2 guidance, the analyst tells investors. After a selloff, valuation is "supportive," but AI-discovery risk and Tax execution keep the firm at Equal Weight despite what it sees as a "strategically positive" Mailchimp exit.
  • KEYS Morgan Stanley analyst Meta Marshall lowered the firm's price target on Keysight Technologies to $400 from $425 and keeps an Overweight rating on the shares. The AI opportunity is broadening across customers, architectures and stages of development, says the analyst, who calls Keysight "a Swiss-army knife way to play AI." Following earnings, the firm is raising estimates, but lowering its price target as it rolls to FY28 given a broader AI valuation pullback.
  • WMT Morgan Stanley raised the firm's price target on Walmart to $135 from $125 and keeps an Overweight rating on the shares. The e-commerce flywheel continues to drive earnings, offsetting deleverage from freight, self-insurance and last mile delivery expense, says the analyst, who adds that price investments support continued share gains and widen the competitive moat.
  • BBWI Morgan Stanley lowered the firm's price target on Bath & Body Works to $21 from $22 and keeps an Equal Weight rating on the shares. Q3 results reinforce the firm's caution on a growth inflection in FY27, while incremental tariff and input cost headwinds add potentially underappreciated margin risk, the analyst tells investors.
  • TTWO Morgan Stanley notes that Sensor Tower estimated $1.8B of gross sales, or 19M copies sold, for GTA VI through yesterday's launch morning, putting the firm's 30M games sold estimate for this quarter "within reach on day 1." GTA VI launched against high expectations and "managed to vastly exceed them," adds the analyst, who keeps an Overweight rating and $280 price target on Take-Two shares.

NEEDHAM

  • BILL Needham analyst Scott Berg downgraded Bill to Hold from Buy without a price target after the company entered into a definitive agreement to be acquired for $63.25 per share in cash.

OPPENHEIMER

  • BILL Oppenheimer downgraded Bill to Perform from Outperform without a price target after the company agreed to be acquired by TPG in partnership with Corpay for $63.25 per share. The firm views the transaction as a reasonable outcome for Bill.

PIPER SANDLER

  • INTU Piper Sandler analyst Billy Fitzsimmons lowered the firm's price target on Intuit to $270 from $290 and keeps an Underweight rating on the shares. The firm notes the company reported a modest Q1 revenue beat of 1.2%, but lowered the FY27 revenue growth midpoint to up 8.3% year-over-year due to reduced expectations for Credit Karma. The quarter was mixed, as healthy Global Business Solutions and Online Ecosystem revenue was offset by weaker Consumer growth, Piper adds.
  • WMT Piper Sandler raised the firm's price target on Walmart to $138 from $128 and keeps an Overweight rating on the shares following a modest Q3 EPS beat and raise. Q3 Walmart U.S. comparable sales remained below historical levels at 2.9%, but management characterized their customer as stable and resilient and expressed confidence in a strong Holiday season. Walmart remains a safe haven for steady growth with continued market share gains, impressive operating initiatives, and strong growth from high margin revenue streams, adds Piper.
  • WSM Piper Sandler raised the firm's price target on Williams-Sonoma to $287 from $286 and keeps an Overweight rating on the shares following Q3 results that missed elevated expectations. Full year guidance was reiterated, but freight headwinds are worse than 3 months ago. All in, Williams-Sonoma is still taking share in a challenged industry backdrop, freight headwinds are transitory, and the company has a number of initiatives in place to drive revenue healthy comp growth, Piper says.

RBC CAPITAL

  • BRKR RBC Capital analyst Dan Leonard last night initiated coverage of Bruker with a Sector Perform rating and $60 price target. The firm says Bruker's innovation in scientific instruments is balanced against an over-reliance on semiconductor capital equipment for its next cycle of outperformance. RBC says it could become more constructive on the shares with an improvement in Bruker's core tools and diagnostics businesses, which it believes would better balance the company's growth drivers.
  • VVV RBC Capital raised the firm's price target on Valvoline to $48 from $46 and keeps an Outperform rating on the shares. The stock cleared an elevated buyside bar and provided better initial FYY7 guidance than anticipated, the analyst tells investors in a research note. Current demand elasticity leads the management to expect transactions will remain flat or slightly positive in FY27, and the company remains confident that they'll be able to hold consumer prices even as base oil costs eventually fall, RBC added.
  • PLUG RBC Capital lowered the firm's price target on Plug Power to $1.25 from $2 and keeps a Sector Perform rating on the shares. The company's 8th annual symposium reinforced the focus on scaling the material handling and electrolyzer businesses, improvement in fuel and service margins, and continued optimization of the balance sheet, the analyst tells investors in a research note.

ROSENBLATT

  • CALX Rosenblatt reiterates a Buy rating on Calix with a $55 price target after spending time with management. Calix One contracts more than doubled in Q3 after the March re-platform slowed Q2, and management expects Q4 to be the biggest cloud quarter in company history, the analyst tells investors in a research note. The firm says that while memory costs are still rising, it is at a moderating rate, and Calix sees gross margin returning toward 60% as costs normalize. Rosenblatt expects multi-dwelling units, hospitality and internal AI productivity supporting the company's growth and operating leverage in 2027.

STIFEL

  • CRDO Stifel analyst Tore Svanberg lowered the firm's price target on Credo Technology to $250 from $310 and keeps a Buy rating on the shares. The firm expects a beat and raise report on AEC strength and optics execution, but lowered its target ahead of earnings to reflect multiple compression across the semiconductor industry.
  • ESTC Stifel lowered the firm's price target on Elastic to $105 from $120 and keeps a Buy rating on the shares. Elastic posted "solid" Q2 results, says the analyst, who believes after two strong quarters that the company is "finally beginning to hit its consistency stride," which should drive the multiple higher in coming quarters.
  • MRVL Stifel lowered the firm's price target on Marvell to $280 from $370 and keeps a Buy rating on the shares. With October quarter preliminary revenue announced already, the firm sees "modest EPS upside," the analyst tells investors in a preview.
  • TMDX Stifel raised the firm's price target on TransMedics to $80 from $70 and keeps a Hold rating on the shares. Despite a "mostly positive" Q3, weak quarter-to-date trends in Q4 deepen the firm's core business concerns, the analyst tells investors.
  • WSM Stifel lowered the firm's price target on Williams-Sonoma to $260 from $290 and keeps a Buy rating on the shares. Following Q3, the firm lowered its FY26 and FY27 EPS estimates, yet remain "constructive," the analyst tells investors.

SUSQUEHANNA

  • GLOB Susquehanna lowered the firm's price target on Globant to $66 from $70 and keeps a Positive rating on the shares. The firm said the company's GLOB's AI-native pivot gained traction across its largest clients in 3Q. While the revenue was in line, the firm sees the Glob.AI as the KPI to watch.
  • FWRD Susquehanna analyst Christopher Stathoulopoulos raised the firm's price target on Forward Air to $29 from $25 and keeps a Positive rating on the shares. The firm updated its model following Q3 results as they raised Q4 and 2027 estimates. The target change is derived by applying a sum-of-theparts valuation framework.

TD COWEN

  • BILL TD Cowen analyst Jared Levine downgraded Bill (BILL) to Hold from Buy with a price target of $63, down from $76, after the company entered into an agreement to be acquired by TPG and Corpay (CPAY) for $63.25 per share. TD expects shareholders to approve the deal "despite a lower than expected offer." The firm previously viewed $74 per share as a reasonable takeout price.
  • UNH TD Cowen upgraded UnitedHealth to Buy from Hold with a price target of $455, up from $402. TD also makes UnitedHealth a 2027 best idea. The firm sees a "credible path" toward mid- to high-teens earnings growth through at least 2028 for UnitedHealth given Medicare Advantage benefit design, an Optum Health recovery, and commercial improvement. TD views the company see an "attractive story."
  • HUM TD Cowen upgraded Humana to Buy from Hold with a price target of $485, up from $430. The firm sees a "relatively clear path towards a meaningful step-up" in Humana's 2027 earnings growth and greater than $40 in earnings per share in 2028. The company's cost trends may moderate and its 2026 Medicare Advantage stars litigation "offers further optionality," the analyst tells investors in a research note. TD says Humana's valuation is "not stretched" at current share levels.
  • EXPD TD Cowen analyst Jason Seidl upgraded Expeditors to Hold from Sell with a price target of $196, up from $189, following its first investor day since 2015. The company outlined a long-term growth strategy of low- to mid-double-digit annual earnings growth through new growth verticals, productivity growth, and buybacks, the analyst tells investors in a research note. TD cites Expeditors' productivity and capital allocation tailwinds for the upgrade.
  • WSM TD Cowen lowered the firm's price target on Williams-Sonoma to $265 from $300 and keeps a Buy rating on the shares following the earnings report. The company's earnings were in line on better EBIT margin but softer comps, the analyst tells investors in a research note. TD believes reaccelerating Pottery Barn will be necessary for the stock's multiple to expand from current levels.
  • WMT TD Cowen analyst Max Rakhlenko raised the firm's price target on Walmart to $147 from $125 and keeps a Buy rating on the shares. The firm views the company's Q3 report as solid. Walmart's key e-commerce businesses continued to accelerate and drove stronger incrementals, the analyst tells investors in a research note. TD expects further "outsized" e-commerce growth in the coming quarters for Walmart, which it thinks will support margin improvement.
  • VVV TD Cowen raised the firm's price target on Valvoline to $43 from $40 and keeps a Buy rating on the shares. The firm views the company's fiscal 2027 outlook as strong. Valvoline's comps outlook of 5%-7% looks conservative and should track at least to the high-end as long as transactions can remain positive, the analyst tells investors in a research note.

TRUIST

  • EVH Truist upgraded Evolent Health to Buy from Hold with an unchanged price target of $6. The firm says that since its June downgrade, Evolent's visibility into 2027 has improved, with $150M of EBITDA "increasingly looking achievable" as Highmark and Aetna mature. Meanwhile, the Medicare-for-All and CRUSH proposal concerns "are being painted with too broad a brush," the analyst tells investors in a research note. Truist believes Evolent shares already discount substantial policy and execution risk.

UBS

  • BILL UBS downgraded Bill (BILL) to Neutral from Buy with a price target of $63.25, down from $64, after the company agreed to be acquired by TPG, in partnership with Corpay (CPAY), for $63.25 per share in an all-cash transaction. UBS believes the transaction will close in the first half of 2027.
  • INTU UBS lowered the firm's price target on Intuit to $315 from $360 and keeps a Neutral rating on the shares. Intuit's Credit Karma slowdown and weaker Q2 revenue guidance raise growth concerns alongside AI disruption and moderating Global Business Solutions Group new-logo growth, the analyst tells investors in a research note.

WELLS FARGO

  • SUPN Wells Fargo analyst Tianqi Hang initiated coverage of Supernus with an Overweight rating and $54 price target. The firm sees a "meaningful valuation disconnect" at current share levels. Supernus' current share price does not fully reflect Sublocade's value and assigns little to no value to Qelbree, Onapgo, and Zurzuvae, the analyst tells investors in a research note. Wells sees the company's 2027 guidance and earnings as potential catalysts for the valuation gap to narrow.
  • INTU Wells Fargo lowered the firm's price target on Intuit to $320 from $330 and keeps an Equal Weight rating on the shares. Resilient Global Business Solutions growth with online ecosystem up 20% and cont. mid-market momentum was overshadowed by weaker-than-expected Credit Karma, impacted both by macro and changing consumer behavior, the firm notes.
  • ROST Wells Fargo analyst Ike Boruchow lowered the firm's price target on Ross Stores to $215 from $242 and keeps an Equal Weight rating on the shares. Q3 was simply not good enough, the firm says. While Wells doesn't question the company's absolute fundamentals, the print was weaker than most expected and should universally bring buyside models lower.
  • KEYS Wells Fargo lowered the firm's price target on Keysight Technologies to $350 from $405 and keeps an Overweight rating on the shares. The firm sees Q4 results and FY27 initial guide as positive amid continued AI and broader T&M demand strength. With Wells' view of demand sustainability, confidence in supply improvement, and strong operating leverage ahead, the firm increases estimates.
  • VVV Wells Fargo raised the firm's price target on Valvoline to $42 from $40 and keeps an Overweight rating on the shares. While Q4 was in-line, the firm attributes the sharp outperformance to better-than-feared FY27 guidance, signs that product cost pressures peaked, and ongoing share gains/fundamental progress. Long-term opportunity looks compelling, adds Wells.

Rating abbreviations…

***OP = Outperform

***SP = Sector Perform

***UP = Underperform

***OW = Overweight

***EW = Equal-weight

***UW = Underweight

 

 

 

 

 

***Report powered by thefly.com***

What’s on Tap Weekly Calendar

 

Monday November 23rd

Economic Calendar: 

  • 8:30 AM ET                   National Activity Index for October
  • 9:45 AM ET S&P Global Manufacturing PMI, Nov-flash
  • 9:45 AM ET S&P Global Services PMI, Nov-flash
  • 9:45 AM ET S&P Global Composite PMI, Nov-flash
  • 1:00 PM ET US Treasury to sell $69B in 2-year notes

Earnings Calendar:

  • Earnings Before the Open: CRGO THCH VNET
  • Earnings After the Close: A ALCO CMP DAC FLNC HPE J PFLT PNNT SMTC SYM TUYA ZM

Tuesday November 24th

Economic Calendar: 

  • 7:45 AM ET ICSC Weekly Retail Sales
  • 8:55 AM ET                   Johnson/Redbook Weekly Sales
  • 9:00 AM ET                   Monthly Home Prices M/M for September
  • 9:00 AM ET                   CaseShiller 20-city index M/M for September
  • 10:00 AM ET                 Consumer Confidence for November
  • 10:00 AM ET                 Richmond Fed Manufacturing for November
  • 1:00 PM ET US Treasury to sell $70B in 5-year notes
  • 4:30 PM ET API Weekly Inventory Data

Earnings Calendar:

  • Earnings Before the Open: ADI AMTM ANF BBY BILI BURL BZUN DKS DLTR DY ITRN KC KSS MDT MMED SHOE SJM TIGR TITN VALN ZH
  • Earnings After the Close: ADSK AMBA BBAR DELL HPQ NOAH NTNX QFIN URBN WDAY

Other Key Events:

  • Deutsche Bank Business Services, Leisure and Transport Conference, 11/24, in London

Wednesday November 25th

Economic Calendar: 

  • 7:00 AM ET MBA Mortgage Applications Data
  • 8:30 AM ET                   Personal Income M/M for October
  • 8:30 AM ET                   Personal Spending M/M for October
  • 8:30 AM ET PCE Price Index M/M for October
  • 8:30 AM ET PCE Price Index Y/Y for October
  • 8:30 AM ET                  Core PCE Price Index M/M for October
  • 8:30 AM ET                  Core PCE Price Index Y/Y for October
  • 8:30 AM ET                  Gross Domestic Product (GDP) Q3-2nd est
  • 8:30 AM ET GDP Consumer Spending for Q3-2nd est.
  • 8:30 AM ET GDP Price Deflator for Q3-2nd est.
  • 8:30 AM ET GDP PCE Price Index M/M for Q3 2nd est.
  • 8:30 AM ET GDP Core PCE Price Index Y/Y for Q3 2nd est.
  • 10:00 AM ET                 New Home Sales M/M for October
  • 10:30 AM ET                 Weekly EIA Inventory Data
  • 1:00 PM ET US Treasury to sell $44B in 7-year notes

Earnings Calendar:

  • Earnings Before the Open: BZ DE DSX GDS GOTU HDL LI
  • Earnings After the Close: FINV

Thursday November 26th

Economic Calendar: 

  • U.S. stock and bond markets closed in observance of Thanksgiving Day holiday

Friday November 27th

Economic Calendar: 

  • U.S. stock markets close at 1:00 PM ET and bond markets at 2:00 pm et.1:00 PM ET
  • 8:30 AM ET                   Weekly Jobless Claims
  • 8:30 AM ET                   Weekly Continued Claims
  • 8:30 AM ET                   Advance Goods Trade Balance for October

 

 

.

As a value-added service exclusive to Regal Securities account holders, The Hammerstone Report is available to read daily on the trading platform.

Hammerstone Inc. (the “Report”) provides information and data and does NOT provide any individual investment advice or money management assistance and does NOT attempt to influence the sale or purchase of securities. The Report is intended for informational purposes only and does not claim to be actionable for investment decisions. The information contained in the Report has been obtained from sources deemed to be reliable but is not represented to be complete, and it should not be relied upon as such. The Report does not purport to be a complete analysis of any security, issuer, or industry and is not an offer or a solicitation of an offer to buy or sell any securities. The Report is prepared for general information purposes only and does not consider the specific investment objectives, financial situation, and particular needs of any individual subscriber, person, or entity.

Content is provided for educational and informational purposes only and Regal Securities cannot attest to its accuracy or completeness. No information provided has been endorsed by Regal Securities and does not constitute a recommendation by Regal Securities to buy or sell a particular investment. You are solely responsible for your own investment decisions and Regal Securities makes no investment recommendations and does not provide financial, tax, or legal advice. Regal Securities may provide links to internet sites maintained by third parties. Unless expressly stated otherwise, links in these reports are not sponsored by nor are they the responsibility of Regal Securities. Regal Securities has not verified the content, accuracy, or opinions expressed on any links in these reports and disclaims any warranty or liability for damages associated therewith.

Copyright 2006-2026 Regal Securities, Inc., Member FINRA/SIPC | Important Disclosures

Your privacy is important to us; see our Privacy Policy for details.

Regal Securities, 950 Milwaukee Ave., Ste. 102, Glenview, IL 60025
Website: www.regalsecurities.com | Toll-free: 1-877-488-6534
Representatives are available Monday through Friday from 8:00 a.m. to 5:00 p.m. EST.